Drs Ahmed Zayed and Mark S. Freedman review emerging therapies in the pipeline and unmet needs in the multiple sclerosis treatment landscape, as well as take-home thoughts.
The director of the Comprehensive Epilepsy Center—Sleep Center at NYU Langone provided perspective on the overlap in characteristics of sleep disorders and the necessary approach to ensuring accurate diagnosis and initial treatment. [WATCH TIME: 5 minutes]
At the 2023 AAN Annual Meeting, the neuromuscular disease specialist and professor of neurology at the University of Kansas Medical Center talked about the phase 3 study investigating ataluren for Duchenne muscular dystrophy. [WATCH TIME: 5 minutes]
The chief executive officer and co-founder of Linus Health discussed screening tools for early cognitive decline and overcoming the complexities with using new-age technology. [WATCH TIME: 3 minutes]
Key opinion leaders in multiple sclerosis (MS) discuss the future of relapsing MS management and unmet needs.
The duo from Montefiore Medical Center discussed aspects of their recently published recommendations on neonatal seizure diagnosis that need further examining.
“Is more always better?”: The age-old question is more relevant than ever as clinicians and patients alike navigate an increasingly crowded MS treatment landscape.
Proper diagnosis and effective treatment planning can drastically improve quality of life for individuals with migraine.
Drs Richard S. Isaacson and Marc E. Agronin look to the future of treating Alzheimer disease with the emphasis on early diagnosis.
Discussing data from an early safety study, the chief scientific officer of FibroBiologics commented on the benefits of a staggered approach to their clinical research in multiple sclerosis. [WATCH TIME: 5 minutes]
Episode 38 of the AUPN Leadership Minute features Muhammad "Mud" Alvi, MD, of West Virginia University Robert C. Byrd Health; and David B. Watson, MD, of West Virginia University Robert C. Byrd Health. [WATCH TIME: 5 minutes]
The chief of the Movement Disorders Division at Mass General Hospital discussed the challenges medical students face in pathing their career and the importance of a strong mentor figure. [WATCH TIME: 6 minutes]
The Lillehei professor in stem cell and regenerative cardiovascular medicine at the University of Minnesota talked about the potential of investigating inducted pluripotent stem cells in neuromuscular diseases at MDA’s 2023 conference. [WATCH TIME: 5 minutes]
The research assistant professor at the Buffalo Neuroimaging Analysis Center provided context on how different forms of multiple sclerosis impact cognitive decline in patients. [WATCH TIME: 4 minutes]
The director of the Pediatric Headache Program at the Children’s Hospital of Philadelphia talked about the usage of an integrated EHR questionnaire to improve the likelihood of specific diagnosis in pediatric headache. [WATCH TIME: 5 minutes]
Successful epilepsy surgery in adults has been followed by forced normalization, depression, and memory issues, resulting in questions about the use of the metrics in the study of broader outcomes—a problem even more prominent in pediatric epilepsy surgery.
The Palatucci Advocacy Leadership Forum, or PALF, sponsored by the American Academy of Neurology, gives neurologists and trainees tools to successfully advocate for their ideas and develop their identity as physician advocates.
Drs Atri, Cohen, Sabbagh and McDade share their enthusiasm and optimism about the future outlook for Alzheimer’s disease.
Sucheta M. Joshi, MD, MS, FAES, FAAP, and Nicholas Beimer, MD, discussed the reasons why EpiTRAQ may influence earlier discussions with patients prior to the epilepsy transition process.
The director of the Comprehensive Care MS Center at Texas Tech University Health Sciences Center talked about findings from a subgroup analysis of Hispanic or Latin patients from the N-MOmentum trial presented at ACTRIMS Forum 2024. [WATCH TIME: 3 minutes]
Achieving greater diversity in study populations is a focus of increasing scrutiny, priority, and funding in all medical research, including studies enrolling individuals on the continuum of prodromal Alzheimer disease, mild cognitive impairment, and Alzheimer disease.
The chief medical officer of Acadia Pharmaceuticals provided commentary on a caregiver analysis assessing beneficial experiences with trofinetide in patients with Rett syndrome. [WATCH TIME: 4 minutes]
The postdoctoral researcher in the department of neurology at Johns Hopkins School of Medicine discussed findings from a study on the impact of indole 3-lactate supplementation in animal models of multiple sclerosis. [WATCH TIME: 4 minutes]
Closing their discussion on insomnia, panelists share final thoughts and advice for community physicians.
The codirector of the ALS Center at Washington University School of Medicine detailed the reasons for hope within the ALS space and the promising innovations in the coming future. [WATCH TIME: 4 minutes]
Episode 39 of the AUPN Leadership Minute features Donald S. Higgins Jr, MD, of Veterans Health Administration, Albany Medical College; and Alexandra Nelson, MD, PhD, of the University of California San Francisco. [WATCH TIME: 5 minutes]
The associate professor of pediatrics in neurology and epilepsy at Northwestern University Feinberg School of Medicine discussed the FDA-cleared phase 1/2 trial of an exon 50 skipping therapy to address the specific mutations causing Duchenne muscular dystrophy. [WATCH TIME: 6 minutes]
The chair of the American Migraine Foundation spoke about the insight gleaned from a recent survey the foundation conducted assessing links between mental health and migraine care. [WATCH TIME: 4 minutes]
Neurology experts discuss where BTKi’s fit in the multiple sclerosis treatment continuum.